These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27103382)

  • 1. Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis.
    Kreuter M; Wijsenbeek MS; Vasakova M; Spagnolo P; Kolb M; Costabel U; Weycker D; Kirchgaessler KU; Maher TM
    Eur Respir J; 2016 Jun; 47(6):1776-84. PubMed ID: 27103382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Warfarin Use Is Associated with Increased Mortality at One Year in Patients with Idiopathic Pulmonary Fibrosis.
    Naqvi SF; Sohail AH; Lakhani DA; Maurer J; Sofka S; Hadi YB
    Pulm Med; 2021; 2021():3432362. PubMed ID: 34868680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulant therapy for idiopathic pulmonary fibrosis.
    Kubo H; Nakayama K; Yanai M; Suzuki T; Yamaya M; Watanabe M; Sasaki H
    Chest; 2005 Sep; 128(3):1475-82. PubMed ID: 16162746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis.
    Kreuter M; Bonella F; Maher TM; Costabel U; Spagnolo P; Weycker D; Kirchgaessler KU; Kolb M
    Thorax; 2017 Feb; 72(2):148-153. PubMed ID: 27708114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.
    Noth I; Anstrom KJ; Calvert SB; de Andrade J; Flaherty KR; Glazer C; Kaner RJ; Olman MA;
    Am J Respir Crit Care Med; 2012 Jul; 186(1):88-95. PubMed ID: 22561965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE.
    Kolonics-Farkas AM; Šterclová M; Mogulkoc N; Kus J; Hájková M; Müller V; Jovanovic D; Tekavec-Trkanjec J; Littnerová S; Hejduk K; Vašáková M
    Drug Saf; 2020 Oct; 43(10):971-980. PubMed ID: 32734423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.
    Kreuter M; Spagnolo P; Wuyts W; Renzoni E; Koschel D; Bonella F; Maher TM; Kolb M; Weycker D; Kirchgässler KU; Costabel U
    Respiration; 2017; 93(6):415-423. PubMed ID: 28399537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia: a nonrandomized prospective study.
    Abe M; Tsushima K; Matsumura T; Ishiwata T; Ichimura Y; Ikari J; Terada J; Tada Y; Sakao S; Tanabe N; Tatsumi K
    Drug Des Devel Ther; 2015; 9():5755-62. PubMed ID: 26566367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coagulation and anticoagulation in idiopathic pulmonary fibrosis.
    Crooks MG; Hart SP
    Eur Respir Rev; 2015 Sep; 24(137):392-9. PubMed ID: 26324800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of anticoagulant therapy for idiopathic pulmonary fibrosis in real life practice.
    Tomassetti S; Ruy JH; Gurioli C; Ravaglia C; Buccioli M; Tantalocco P; Decker PA; Cavazza A; Dubini A; Agnoletti V; Gurioli C; Casoni GL; Romagnoli M; Poletti V
    Sarcoidosis Vasc Diffuse Lung Dis; 2013 Aug; 30(2):121-7. PubMed ID: 24071883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How does comorbidity influence survival in idiopathic pulmonary fibrosis?
    Hyldgaard C; Hilberg O; Bendstrup E
    Respir Med; 2014 Apr; 108(4):647-53. PubMed ID: 24529739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Anticoagulation and Survival in Interstitial Lung Disease: An Analysis of the Pulmonary Fibrosis Foundation Patient Registry.
    King CS; Freiheit E; Brown AW; Shlobin OA; Aryal S; Ahmad K; Khangoora V; Flaherty KR; Venuto D; Nathan SD
    Chest; 2021 Apr; 159(4):1507-1516. PubMed ID: 33075376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of inhaled heparin in idiopathic pulmonary fibrosis.
    Markart P; Nass R; Ruppert C; Hundack L; Wygrecka M; Korfei M; Boedeker RH; Staehler G; Kroll H; Scheuch G; Seeger W; Guenther A
    J Aerosol Med Pulm Drug Deliv; 2010 Jun; 23(3):161-72. PubMed ID: 20109123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
    Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Volume and Characteristics of Intracerebral Hemorrhage with Direct Oral Anticoagulants in Comparison with Warfarin
.
    Adachi T; Hoshino H; Takagi M; Fujioka S;
    Cerebrovasc Dis Extra; 2017; 7(1):62-71. PubMed ID: 28376486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
    Agarwal S; Bennett D; Smith DJ
    Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for acute exacerbation of idiopathic pulmonary fibrosis--Extended analysis of pirfenidone trial in Japan.
    Kondoh Y; Taniguchi H; Ebina M; Azuma A; Ogura T; Taguchi Y; Suga M; Takahashi H; Nakata K; Sugiyama Y; Kudoh S; Nukiwa T
    Respir Investig; 2015 Nov; 53(6):271-8. PubMed ID: 26521104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Respiratory comorbidities and risk of mortality in hospitalized patients with idiopathic pulmonary fibrosis.
    Oda K; Yatera K; Fujino Y; Kido T; Hanaka T; Sennari K; Fushimi K; Matsuda S; Mukae H
    Respir Investig; 2018 Jan; 56(1):64-71. PubMed ID: 29325684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes after hospitalization in idiopathic pulmonary fibrosis: a cohort study.
    Brown AW; Fischer CP; Shlobin OA; Buhr RG; Ahmad S; Weir NA; Nathan SD
    Chest; 2015 Jan; 147(1):173-179. PubMed ID: 25188694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.